Core Viewpoint - The company will present Phase II clinical data for its novel fully human only heavy chain anti-CTLA-4 antibody, HBM4003, in combination with Tislelizumab for microsatellite stable metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) annual meeting in Berlin from October 17 to October 21, 2025 [1] Group 1 - HBM4003 is developed from the HCAb Harbour Mice® platform and is the first fully human only heavy chain antibody to enter clinical stages globally [1] - Compared to traditional anti-CTLA-4 antibodies, HBM4003 shows significantly enhanced Treg cell clearance and optimized pharmacokinetics, contributing to improved safety [1] - HBM4003 enhances antibody-dependent cellular cytotoxicity (ADCC), increasing the potential for selective clearance of intratumoral Treg cells, which may overcome efficacy and toxicity limitations of existing CTLA-4 therapies [1] Group 2 - The company has initiated a global development plan for HBM4003 targeting various solid tumors, employing an adaptive treatment design [1] - Positive efficacy and safety data have been observed in clinical trials for advanced solid tumors, both as monotherapy and in combination with PD-1 inhibitors for melanoma, colorectal cancer, neuroendocrine cancer, and hepatocellular carcinoma [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司將於2025年10月17日至10 月21日在德國柏林舉辦的2025年歐洲腫瘤內科學會(ESMO)年會上，公佈其新一 代全人源僅重鏈抗CTLA-4抗體普魯蘇拜單抗(HBM4003)聯合替雷利珠單抗治療 微衛星穩定型(MSS)轉移性結直腸癌(mCRC)的II期臨床數據。 初步療效和安全性數據將在2025年ESMO大會的壁報環節進行展示。相關壁報的 具體信息如下： 入選摘要的全文將在線發表於ESMO網站。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 於2025年ESMO大會公佈HBM4003聯合替雷利珠單抗治療微衛 星穩定型轉移性結直腸癌的II期臨床數據 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 正面盈利警告 本公告乃由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）遵 照香港聯合交易所有限公司《證券上市規則》（「上市規則」）第13.09條及證券及期 貨條例（「證券及期貨條例」）（香港法例第571章）第XIVA部的規定而作出。 本公司董事（「董事」）會（「董事會」）欣然知會本公司股東（「股東」）及潛在投資 者，根據對本集團截至2025年6月30日止六個月（「報告期間」）未經審計管理賬目 之初步審閱，預期截至2025年6月30日止六個月的溢利介乎約68百萬美元（相當於 約5.32億港元）至約74百萬美元（相當於約5.79億港元）。預期溢利增加主要歸因 於： 本公司股東及潛在投資者於買賣本公司證券時，務請審慎行事。如有疑問，建議 股東及潛在投資者尋求專業人士或財 ...

Core Insights - The Chinese biotech sector is experiencing a structural revaluation, with the Hong Kong innovative drug sector showing a year-to-date increase of over 60% as of June 2025, driven by significant global collaborations in innovative drugs [1] - Hengrui Medicine has become a key player in the internationalization of Chinese innovative drugs, achieving over $10 billion in overseas transactions, including a $45.75 billion deal with AstraZeneca and a $6.7 billion partnership with Otsuka Pharmaceutical [1][2] - The company has seen its stock price rise over 300% in the first half of 2025 and is one of the few Hong Kong-listed companies that have achieved profitability for two consecutive years, indicating a sustainable business model [1][2] Group 1: Industry Trends - The Chinese innovative drug sector is transitioning from a focus on the quantity of pipelines to the value of technology, with companies like BeiGene and Ilyas successfully selling products overseas, where international sales now account for over half of their revenue [2] - The industry faces challenges, including the uncertainty of future product launches and the sustainability of business development (BD) transactions, which can lead to significant revenue fluctuations [2] - The high-risk nature of innovative drug development necessitates that companies find sustainable paths to navigate the "valley of death" in the industry [2] Group 2: Hengrui Medicine's Strategy - Hengrui Medicine has been labeled the "King of BD" due to its frequent license-out transactions, which are strategically aligned with its core technology platform [2][3] - The company has established a strong global collaboration network, with over 300 projects in partnership with leading firms like AstraZeneca and Pfizer, focusing on providing comprehensive preclinical solutions [4] - Hengrui Medicine aims to become a "new infrastructure" for global antibody drugs, leveraging its technology platform to enhance its role in the global pharmaceutical supply chain [5][6] Group 3: Technological Advancements - The integration of AI and big data is transforming drug development, with Hengrui Medicine utilizing AI to optimize antibody efficacy and explore new therapeutic targets [7] - The company has partnered with Insilico Medicine to advance AI-driven antibody discovery, enhancing its capabilities in treating complex diseases [7] - Hengrui Medicine is also focusing on expanding its self-developed pipeline, particularly in the inflammation and immunology sectors, with several candidates nearing clinical trials [8] Group 4: Market Challenges and Opportunities - The Chinese innovative drug industry is thriving but faces issues such as homogenization and intense competition, necessitating diverse business models for sustainable growth [8] - The company emphasizes the importance of recognizing the long and complex nature of the innovative drug industry, advocating for a coexistence of various development models to create a sustainable innovation matrix [8]

Summary of Key Points Core Viewpoint - A number of companies, including AIA Insurance, Yum China, and Mengniu Dairy, conducted share buybacks on July 11, 2025, with AIA Insurance having the largest buyback amount of 280 million yuan for 4 million shares [1][2]. Group 1: Buyback Details - AIA Insurance (01299) repurchased 4 million shares for 280 million yuan, totaling 124 million shares repurchased this year, representing 1.157% of its total share capital [2]. - Yum China (09987) repurchased 16,500 shares for 6.24 million yuan, with a year-to-date total of 241,690 shares, accounting for 0.650% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 20,000 shares for 3.28 million yuan, with a total of 365,000 shares repurchased this year, representing 0.093% of its total share capital [2]. Group 2: Other Notable Buybacks - China International Marine Containers (02039) repurchased 628,600 shares for 4.11 million yuan, totaling 5.13 million shares repurchased this year, which is 0.170% of its total share capital [2]. - Beike-W (02423) repurchased 643,500 shares for 4 million yuan, with a total of 769,010 shares repurchased this year, representing 0.213% of its total share capital [2]. - Jieli Trading (08017) repurchased 2 million shares for 2.20 million yuan, with a total of 35.99 million shares repurchased this year, accounting for 6.000% of its total share capital [2].

Macro Insights - The macro policy for the second half of the year may involve non-traditional measures, with a focus on price stability and the marginal improvement of asset prices, particularly in equity products [2][32] - The "anti-involution" policy is expected to drive companies to reduce capital expenditures and clear excess capacity, leading to improved economic supply-demand relationships and enhanced corporate profitability [3][44] Strategy Insights - The "anti-involution" trend is identified as a key driver for a bullish market, with high-quality stocks likely to play a crucial role in pushing indices higher [3][44] - AI is recognized as a core driver of the current technological revolution, creating investment opportunities across multiple industries in the A-share market [3][44] - Key sectors to watch in July include solid-state batteries, domestic computing power, non-bank financials, defense and military, and innovative pharmaceuticals, all showing signs of marginal improvement [3][44] Market Performance - The Shanghai Composite Index closed at 3510.18, reflecting a weekly increase of 1.09% [5][7] - The Shenzhen Component Index closed at 10696.10, with a weekly increase of 1.78% [8] Economic Indicators - The manufacturing PMI rose to 49.7% in June, indicating a slight recovery, while the construction PMI significantly improved to 52.8% due to accelerated infrastructure projects [12][13] - Consumer spending showed mixed results, with significant growth in automobile and home appliance sales driven by government subsidies, while other sectors like clothing and cosmetics remained weak [13][14] Industry Trends - The real estate market continues to face challenges, with declining sales and investment, leading to a negative outlook for related sectors [13][14] - The "anti-involution" policy is expected to address price competition and improve product quality, particularly in the durable consumer goods sector [30][44]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年7月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Insights - The Chinese government emphasizes the importance of strengthening pharmaceutical innovation and research to support public health and the development of innovative drugs and medical devices [1] - The trend of Chinese innovative drugs going global is gaining momentum, with significant increases in business development (BD) transactions and funding [2][3] - The pharmaceutical sector is expected to recover in 2025, driven by high-value BD transactions and an improving policy environment [3][4] Industry Developments - The Chinese innovative drug market is projected to see a surge in international collaborations, with over 80 BD projects completed by 2025, indicating a growing global competitiveness [2] - In Q1 2025 alone, BD transactions reached 41, with a total value of approximately 369.29 billion USD, nearing the total for the previous year [2] - Major transactions include the licensing of PD-1/VEGF dual antibody SSGJ-707 to Pfizer for 60.5 billion USD and the global rights for Tislelizumab to Vor Bio for up to 42.3 billion USD [2] Company Highlights - Companies like 基石药业-B (02616) showcased innovative products at the AACR annual meeting, highlighting their advancements in clinical research [5] - 和誉-B (02256) received priority review for its CSF-1R inhibitor for treating TGCT, indicating regulatory support for innovative therapies [6] - 和铂医药 (02142) entered a significant strategic partnership with AstraZeneca, securing 1.75 billion USD in upfront payments and potential milestone payments totaling up to 44 billion USD [6] - 信达生物 (01801) aims to achieve 20 billion RMB in product sales by 2027, with multiple catalysts expected in the coming years, including potential drug launches and data readouts [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 有關恩凱賽藥的A+++輪融資 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）按自 願基準作出，以知會本公司股東（「股東」）及潛在投資者有關本集團的最新業務進 展。 本公司董事會（「董事會」）欣然宣佈，本公司所投資的公司上海恩凱細胞技術有限 公司（「恩凱賽藥」）近日已完成A+++輪融資，本輪融資由多名投資者參與，融資 近人民幣1億元。所得款項將用於推進其核心NK細胞療法產品候選藥物的臨床試 驗，並支持其產品管線的開發。 此次成功融資反映出恩凱賽藥在NK細胞療法開發領域持續取得突破，表明投資人 對其創新免疫治療平台充滿信心，所獲資金將為加速臨床轉化提供重要支撐。 關於恩凱賽藥 恩凱賽藥是一家生物科技公司，專注於NK細胞療法創新技術的研發。2024年， ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年7月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...